April 29th 2025
A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.
February 26th 2025
FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer Subset
November 30th 2022The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.